Qui sommes-nous ? About us
L'ANSM en bref
About us
Nos engagements
Nos missions
Faciliter l'accès à l'innovation thérapeutique Assurer la sécurité des produits de santé Informer & échanger avec notre environnement
Notre périmètre
Les médicaments Les vaccins Les produits biologiques Les dispositifs médicaux et les dispositifs médicaux de diagnostic in vitro (DMDIV) Les cosmétiques et produits de tatouage
Notre organisation
Nos expertises Nos directions et nos services Nos instances
Déontologie et transparence
Nos exigences déontologiques Notre organisation de la déontologie Rapports du déontologue
Publications institutionnelles
Rapport d'activité 2023 Contrat d’objectifs et de performance Programmes de travail Rapports d'activité
Publications scientifiques
Rejoignez-nous !
Nos métiers Notre politique RH Nos offres d'emploi
Notre agenda
 
Actualités
Nos articles
Nos campagnes
 
Bulletin officiel des actes, décisions et avis
Décisions institutionnelles
Décisions relatives à l'organigramme Désignations et habilitations des inspecteurs Expertise : nomination d'experts ponctuels GIS Epiphare Instances : créations et nominations Nominations et délégations de signature
Décisions liées aux médicaments
Accès dérogatoire Bonnes pratiques Classement substances vénéneuses (Listes I et II - Psychotropes/Stupéfiants) Médicaments biosimilaires Médicaments de médication officinale Médicaments génériques MTI et MTIPP Pharmacopée Programmes d'apprentissage Publicité Rétrocession Stocks de sécurité / Décisions d'interdictions d'exportation
Décisions liées aux produits sanguins et autres produits biologiques
Agréments établissements de transfusion sanguine Questionnaire pré-don
Décisions liées aux médicaments dérivés du plasma
Produits exclus de l'assiette de contribution
Décisions liées aux dispositifs médicaux et dispositifs médicaux de diagnostic in vitro
Agréments Calendrier publicité Organismes notifiés
Injonctions
Décisions de police sanitaire
Médicaments Dispositifs médicaux et dispositifs médicaux de diagnostic in vitro Autres produits
Sanctions financières
Avis
 
Disponibilité des produits de santé
Médicaments
Dispositifs médicaux et dispositifs médicaux de diagnostic in vitro
 
Vos démarches
Industriel
Organismes notifiés
Professionnel de santé
Patient
Chercheur

Our organisation

A+ A-
print Télécharger le texte de cette page au format PDF
> Consultez la version française

Two bodies are tasked with ANSM’s governance: a Management Board, and a Scientific Board.

In addition, since 2019, the Agency’s policy of openness to civil society has resulted in healthcare system users being systematically involved in our consultative bodies of expertise. We are convinced of the need to work alongside patients and healthcare professionals to ensure that our action addresses the challenges that they face on a daily basis.

For this reason, our decisions are based on the opinions of several consultative committees, in which the expertise of representatives of civil society, their perspective, and their vision of the health sector allow objective and informed decision-making.
 

Interface Committees


A direct interface between the ANSM and stakeholders (manufacturers, patient associations, healthcare professionals) is ensured via “interface committees”.

These committees enable regular and constructive dialogue on general matters, in accordance with the rules of transparency that underpin the Agency's operations.

Created and constituted in 2013 by decision of the Director General, they bring together both stakeholder and Agency representatives:
  • The Interface Committee working with patient or healthcare system user associations involved in the health products sector.
  • The Interface Committee working with the College of General Practitioners contributes to greater understanding and consideration of the expectations of general practitioners and helps develop their contribution to the Agency's activities and missions.
  • The Interface Committee working with pharmacist representatives: National Board of Pharmacists and the main pharmaceutical unions, in both the retail sector (FSPF and USPO) and hospital sector (SNPHPU, SYNPREFH). Its objective is to encourage dialogue, to give pharmacists the opportunity to contribute to the ANSM's activities and missions, and to better understand and take into consideration the expectations of pharmacists.
  • Three interface committees with representatives of the pharmaceutical industries, and their associated working groups:
    • Interface Committee working with medicinal product industry representatives;
    • Interface Committee working with medical device and in vitro diagnostic medical device industry representatives;
    • Interface Committee working with professional organisations representing the cosmetic products industries (this committee is no longer active).
In June 2023, the ANSM set up an "Innovation Support" Interface Committee to promote more regular dialogue with players on the ground on innovation support mechanisms for all healthcare products.
Download the rules of procedure of the Interface Committees working with professional organisations representing the health or cosmetic products industries (04/06/2013)

List of Interface Committees

  • "Innovation Support" Interface Committee
  • Interface Committee working with the College of General Practitioners
  • Interface Committee working with patient associations
  • Interface Committee working with medical device and in vitro diagnostic medical device industry representatives
  • Interface Committee working with medicinal product industry representatives
  • Interface Committee working with pharmacist representatives